- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03608007
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
January 6, 2020 updated by: Betta Pharmaceuticals Co., Ltd.
Phase II, Open-Label, Single Arm Study of the Efficacy and Safety of X-396 Capsule in Patients With ROS1 Positive Advanced NSCLC
To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, multicenter, single-arm study in which the efficacy and safety of X-396 capsule (Ensartinib) will be assessed in adult Chinese patients with ROS1-positive (rearrangement or inversion) non-small cell lung cancer (NSCLC).
Approximately 69 patients (59 for never-treated, and 10 for previously treated with crizotinib) with locally advanced or metastatic NSCLC carrying ROS1-rearrangement will be enrolled in the study.
Study Type
Interventional
Enrollment (Anticipated)
69
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Chest hospital affiliated to Shanghai jiao tong university
-
Principal Investigator:
- Shun Lu, Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female or male, 18 years of age or older
- Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic
- Positive for translocation or inversion events involving the ROS1 gene
- Tyrosine kinase inhibitor (TKI) treatment-naive or have previously received no more than one systemic treatment regimen(s) such as chemotherapy (After a 3-week washout period)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Predicted survival ≥ 3 months
- Drug related toxicities were relieved to grade 1, except for hair loss (based on NCI CTCAE v4.03)
- Adequate organ function
- At least 1 measurable tumor lesion as per RECIST v1.1
- Asymptomatic central nervous system (CNS) metastases do not require the use of steroids or anticonvulsants.
- Signed and dated informed consent
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment
Exclusion Criteria:
- Current treatment on another systemic anti-cancer therapy
- Prior therapy specifically directed against ROS1 fusion genes (except for the exploratory arm that will enroll patients pretreated with crizotinib)
- Evidence of active malignancy within last 3 years
- Previous therapeutic clinical trial must have completed at least 4 week prior to initiation of study drug
- Prior surgery or immunotherapy must have completed at least 4 weeks, and radiation must have been completed at least 2 weeks prior to initiation of study drug
- Known interstitial fibrosis or interstitial lung disease
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medication
- Clinically significant cardiovascular disease
- Patients with a known allergy or delayed hypersensitivity reaction to study drug or its excipient
- Pregnant or breast feeding
- Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers
- Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
- Other serious illness or medical condition potentially interfering with the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: X-396 Capsule
Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
|
225 mg once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) based on independent radiology review (IRC) according to RECIST 1.1
Time Frame: 12 weeks
|
ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on IRC.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 36 months
|
OS, defined as time from first dose of X-396 to death due to any cause.
|
36 months
|
ORR based on investigator assessment according to RECIST 1.1
Time Frame: 12 weeks
|
ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as CR or PR, based on investigator's assessment
|
12 weeks
|
Disease control rate (DCR) according to RECIST 1.1
Time Frame: 12 weeks
|
DCR defined as the percentage of patients who have achieved CR, PR and stable disease (SD), based on RECIST 1.1 measured by IRC or investigator
|
12 weeks
|
Intracranial overall response rate (iORR) by IRC and investigator assessment according to RECIST 1.1
Time Frame: 12 weeks
|
iORR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measurable disease in the brain at baseline.
|
12 weeks
|
Progression-free survival (PFS) based on IRC or investigator according to RECIST 1.1
Time Frame: 36 months
|
PFS defined as time from first dose of X-396 capsule to disease progression or death due to any cause, based on RECIST 1.1.
|
36 months
|
Time to progression (TTP) based on IRC or investigator according to RECIST 1.1
Time Frame: 36 months
|
TTP defined as time from first dose of X-396 capsule to disease progression, based on RECIST 1.1.
|
36 months
|
Duration of response (DOR) based on IRC or investigator according to RECIST 1.1
Time Frame: 36 months
|
DOR defined as time from documentation of tumor response (CR or PR) to disease progression or death, based on RECIST 1.1
|
36 months
|
Change From Baseline Scores on the functional assessment of cancer therapy - Lung (FACT-L) quality of life questionnaire
Time Frame: 36 months
|
The FACT-L questionnaire consisted of several major aspects of life (Physical, social/family, emotional, and functional well-being) as well as lung cancer subscale (symptoms, cognitive function, regret of smoking).
Scores for item ranging from 0 (not at all) to 4 (very much).
|
36 months
|
Incidence of patients experiencing adverse events (AE)
Time Frame: 36 months
|
Adverse events are graded according to CTCAE 4.03
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Shun Lu, phd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2018
Primary Completion (Anticipated)
March 1, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
May 16, 2018
First Submitted That Met QC Criteria
July 23, 2018
First Posted (Actual)
July 31, 2018
Study Record Updates
Last Update Posted (Actual)
January 9, 2020
Last Update Submitted That Met QC Criteria
January 6, 2020
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTP-42723
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on X-396 Capsule
-
Sichuan UniversityBetta Pharmaceuticals Co., Ltd.Not yet recruitingNon-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
-
Fudan UniversityBetta Pharmaceuticals Co., Ltd.UnknownNonsmall Cell Lung Cancer | Brain Metastases
-
Betta Pharmaceuticals Co., Ltd.Active, not recruitingNon-Small Cell Lung CancerChina
-
Hebei Medical University Fourth HospitalRecruitingNon-small Cell Lung CancerChina
-
Xcovery Holding Company, LLCCompletedAdvanced Solid Tumors | Non-small Cell Lung CancerUnited States
-
Betta Pharmaceuticals Co., Ltd.CompletedSolid Tumor | Non-Small Cell Lung Cancer MetastaticChina
-
Syneos HealthSynerK Pharmatech (Suzhou) LimitedRecruitingElevated Low-Density Lipoprotein CholesterolAustralia
-
Xcovery Holdings, Inc.CompletedBioequivalencyUnited States
-
Xcovery Holding Company, LLCAvailableNon-Small Cell Lung Cancer | ALK Gene Rearrangement PositiveUnited States
-
Betta Pharmaceuticals Co., Ltd.RecruitingNon-small Cell Lung CancerChina